Drug Trial Radar · NCT05303805
Topical Sevoflurane for Treatment of Chronic Leg Ulcers
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
May 2, 2022
Primary completion
Oct 30, 2027
Study completion Jan 31, 2028
Sponsor
- Lead sponsor
- Charles University, Czech RepublicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Faculty Hospital Kralovske Vinohrady
- First posted
- Mar 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with painful non-healing leg ulcer will be enrolled in the clinical single-blinded randomized study. The active treatment group will have sevoflurane applied at approximately 1 ml/cm2 at the start of wound treatment, the control group will only have a standard rinse solution with Cyteal TM (Pierre Fabre Medicament, France). Further treatment will then be carried out in the standard manner. The duration of the study will be 5 days; if the defect heals earlier, it will be terminated early. Exclusion criteria: allergy to sevoflurane, inability to understand the questionnaire Parameters to be monitored will be pain intensity, microbial colonization, appearance and size of the defect
Conditions
- Leg Ulcer
Interventions
SevofluraneDrug
Topical application of 1 mL sevoflurane per 1 cm2 ulcer area once or two times daily.
CytealCombination product
Rinsing and cleaning of ulcer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain intensityTime frame: Continuously for 5 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Faculty Hospital Kralovske Vinohrady
Prague, Czechia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.